A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

Internal tandem duplications in fms-like tyrosine kinase 3 (FLT3-ITDs) are common in acute myeloid leukemia (AML) and confer a poor prognosis. A sensitive and specific assay for the detection of minimal residual disease (MRD) in FLT3-ITD mutated AML could guide therapy decisions. Existing assays for...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood Adv
Päätekijät: Levis, Mark J., Perl, Alexander E., Altman, Jessica K., Gocke, Christopher D., Bahceci, Erkut, Hill, Jason, Liu, Chaofeng, Xie, Zhiyi, Carson, Andrew R., McClain, Valerie, Stenzel, Timothy T., Miller, Jeffrey E.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2018
Aiheet:
Myeloid Neoplasia
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5916006/
https://ncbi.nlm.nih.gov/pubmed/29643105
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018015925
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia